Last reviewed · How we verify
NCT06087627: CLEAR PN
A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine
trial testing Dupilumab SAR231893 (REGN668) in Prurigo Nodularis in 150 participants. Currently enrolling.
6 June 2026
Quick facts
| Lead sponsor | Sanofi |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 27 December 2023 |
| Primary completion | 6 June 2026 |
| Estimated completion | 28 December 2026 |
| Sites | 11 locations across Germany |
Drugs / interventions tested
- Dupilumab SAR231893 (REGN668)
Conditions studied
- Prurigo Nodularis — all drugs for Prurigo Nodularis →
Sponsor
Sanofi — full company profile →
Who can join
18 and older, any sex, with Prurigo Nodularis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prurigo nodularis (PN) is a skin disease characterized by the presence of single to multiple symmetrically distributed, intensively itching nodules. The main symptom is uncontrollable itching leading to prolonged, repetitive, and uncontrollable rubbing, scratching which in turn causes injuries to the skin. In recent years, number of studies evaluating PN, the affected population and the disease burden has increased but PN remains still understudied. This non-interventional study is intended to describe the long-term effectiveness of dupilumab (Dupixent®) in participants aged 18 years or older and suffering from moderate-to-severe PN who receive dupilumab for PN treatment in a real-world setting in Germany according to the prescribing information (Summary of Product Characteristics \[SmPC\]). The decision to initiate dupilumab treatment is made by the treating physician and participant according to the participant's medical need and to the standard of best medical practice. This decision is made independently and before data inclusion in this non-interventional study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New and Emerging Biologics and Jak Inhibitors for the Treatment of Prurigo Nodularis: A Narrative Review.
Bianco M, D'Oria F, Falcidia C, Foggi G, et al · · 2025 · cited 5× · PMID 40282922 · DOI 10.3390/medicina61040631
Verify or expand the search:
- PubMed search for NCT06087627
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dupilumab SAR231893 (REGN668)
Trials testing the same drug.
- NCT03992417 — Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) · active not recruiting
- NCT03620747 — Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up) · Phase 3 · completed
- NCT02912468 — A Controlled Clinical Study of Dupilumab in Patients With Bilateral Nasal Polyps · Phase 3 · completed
- NCT02898454 — Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps · Phase 3 · completed
Other recruiting trials for Prurigo Nodularis
Currently open trials in the same condition.
- NCT06988618 — Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults · recruiting
- NCT06994520 — Efficacy of Topical Cannabidiol for Eczema · Phase 2 · active not recruiting
- NCT06516965 — A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) · Phase 3 · active not recruiting
- NCT06516952 — A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) · Phase 3 · recruiting
- NCT06554509 — Clinical Study of the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Prurigo Nodularis · Phase 2, PHASE3 · recruiting
Other Sanofi trials
Trials by the same sponsor.
- NCT07282795 — Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe · not yet recruiting
- NCT06694025 — Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe. · not yet recruiting
- NCT07222189 — A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Crohn's Dise · Phase 2 · not yet recruiting
- NCT07484230 — A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Partic · Phase 3 · not yet recruiting
- NCT07547436 — A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age Wi · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06087627 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sanofi
- Last refreshed: 13 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06087627.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing